SCHEMBL2749007

SCHEMBL2749007

O=S(=O)(Oc1cc2ccc(Cl)cc2cn1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.48
PDE4C Q08493 3/20 0.48
PDE4D Q08499 3/20 0.48
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CHRM1 P11229 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CNR2 P34972 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HSD11B1 P28845 1/20 0.34
CYP2A6 P11509 1/20 0.33
PTGS1 P23219 3/20 0.33
PTGS2 P35354 2/20 0.33
ALPL P05186 3/20 0.32
ACLY P53396 1/20 0.32
FBP1 P09467 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1396872 0.94 PDE4A (0.48) PDE4APDE4CPDE4DADORA2AADORA1
SCHEMBL2748735 0.84 L3MBTL1 (0.39) PDE4APDE4CPDE4DADORA2AADORA1
SCHEMBL18791386 0.84 PDE4A (0.43) PDE4APDE4CPDE4DADORA2AADORA1
SCHEMBL2749607 0.83 THRB (0.40) PDE4APDE4CPDE4DCA1CA2
SCHEMBL2749293 0.83 THRB (0.46) PDE4APDE4CPDE4DADORA2AADORA1
SCHEMBL127875 0.82 PDE4A (0.46) PDE4APDE4CPDE4DADORA2AADORA1
SCHEMBL2749691 0.82 PIM1 (0.38) PDE4APDE4CPDE4DCA1CA2
SCHEMBL2749231 0.82 NPC1 (0.47) CA1CA2L3MBTL1HSD11B1CYP2A6
SCHEMBL18133374 0.80 HSD11B1 (0.45) PDE4APDE4CPDE4DADORA2AADORA1
SCHEMBL2749443 0.80 PDE4A (0.43) PDE4APDE4CPDE4DADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 PDE4A 2821/4885PDE4C 3015/4885PDE4D 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.